AstraZeneca plc (LON:AZN)‘s stock had its “sell” rating reissued by stock analysts at Shore Capital in a research report issued on Wednesday, May 10th.
A number of other research analysts have also weighed in on the stock. Barclays PLC reissued an “overweight” rating and set a GBX 6,000 ($77.45) price target on shares of AstraZeneca plc in a research report on Monday, March 27th. Goldman Sachs Group Inc set a GBX 3,900 ($50.34) price objective on shares of AstraZeneca plc and gave the stock a “sell” rating in a report on Friday, February 3rd. Deutsche Bank AG restated a “buy” rating and set a GBX 5,500 ($71.00) price objective on shares of AstraZeneca plc in a report on Tuesday, March 21st. HSBC Holdings plc downgraded shares of AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($58.09) target price for the company. in a research note on Friday, April 7th. Finally, Liberum Capital reiterated a “buy” rating and issued a GBX 5,200 ($67.12) target price on shares of AstraZeneca plc in a research note on Tuesday, January 31st. Five equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company. AstraZeneca plc currently has an average rating of “Hold” and an average target price of GBX 5,001.80 ($64.56).
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.